Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL)

By Sirohi Bhawna   Cunningham David   Norman Andy   Last Kim   Chau Ian   Horwich Alan   Oates Jacqui   Chong Geoffrey   Wotherspoon Andrew  

Hematology, Vol. 12, Iss. 2, 2007-04 ,pp. : 149-153

Maney Publishing

Access to resources Recommend Favorite

Rituximab in combination with vinorelbine/gemcitabine chemotherapy in patients with primary refractory or early relapsed T cell rich B cell lymphoma - A pilot study

By Xiros N.   Economopoulos T.   Valsami S.   Rontogianni D.   Fountzilas G.   Raptis S.  

Leukemia Research, Vol. 27, Iss. 12, 2003-12 ,pp. : 1097-1099

Elsevier

Access to resources Recommend Favorite

Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients

By Li J.   Wang L.   Shen Y.   Xia Z.   Chen Y.   Chen Q.   Chen Y.   Zeng X.   You J.   Qian Y.   Shen Z.  

Annals of Hematology, Vol. 86, Iss. 9, 2007-09 ,pp. : 639-645

Springer Publishing Company

Access to resources Recommend Favorite

Tandem myeloablative ¹³¹I-rituximab radioimmunotherapy and high-dose chemotherapy in refractory/relapsed non-Hodgkin lymphoma patients

By Deshayes Emmanuel   Kraeber-Bodéré Françoise   Vuillez Jean-Philippe   Bardiès Manuel   Teulon Isabelle   Pouget Jean-Pierre  

Immunotherapy, Vol. 5, Iss. 12, 2013-12 ,pp. : 1283-1286

Future Medicine

Access to resources Recommend Favorite

Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/ Refractory Diffuse Large B Cell Lymphoma

By  

Current Stem Cell Research & Therapy, Vol. 12, Iss. 1, 2016-12 ,pp. : 14-18

Bentham Science Publishers

Access to resources Recommend Favorite